Biotech Stocks to Watch Today: Agenus, Allergan and Auxilium Pharmaceuticals

Today's top stories in biotech and health care.

Jun 26, 2014 at 9:00AM


Let's take a look at today's top stories in biotech and health care. Keep an eye out for Agenus (NASDAQ:AGEN), Allergan (NYSE:AGN) and Auxilium Pharmaceuticals (NASDAQ:AUXL)

Agenus shares soaring on positive clinical news for its Herpes vaccine
Shares of clinical stage biopharma Agenus are up over 16% in premarket this morning after the company announced that its experimental vaccine for genital herpes simplex virus-2 produced a correlation between a reduction in viral load and an increase in CD8 T cell activation. In November 2013, Agenus previously reported that its vaccine significantly decreased viral shedding with minimal adverse effects. 

Given that herpes simplex virus-2 is one of the fastest growing STD's in the U.S. and is presently incurable, this vaccine could be a major step forward for both the medical community and Agenus alike. Now, this was a phase 2 trial, so the usual caveats about small sample size apply. But you may want to keep tabs on this small-cap biopharma as it pushes this intriguing vaccine into further development.

Allergan may get pushed into a deal with Valeant
Allergan shares are up over 1% this morning following news that Hedge Fund Paulson & Co. purchased 6 million shares of the company and stated that they would like to see the proposed merger take place with Valeant Pharmaceuticals (NYSE:VRX). As a refresher, Bill Ackman's Pershing Square is also a major stakeholder in Allergan and has been aggressively been pushing this deal from the get-go, although management has repeatedly rejected Valeant's overtures.

Yesterday's news shows that hedge funds are starting to put the squeeze on Allergan's brass, so it wouldn't be surprising if an election was called soon to replace the company's directors, in light of their refusal to entertain a bid offer.

On the flip side, I would expect Allergan to now actively pursue a deal of its own with a Shire or another similar company in an attempt to stave off a takeover. Management has made it clear that they believe Allergan should remain an independent entity, so perhaps the only way to make that happen now is to play the M&A game themselves.

Auxilium enters into an agreement to merge with Canadian biotech QLT
Shares of Auxilium Pharmaceuticals are up nearly 18% in premarket following news of a merger with Canandian biotech QLT. In an all-stock deal, Auxilium is buying QLT for its orphan drug candidates indicated for genetic-based diseases of the retina. The deal comes at a 25% premium for QLT shareholders and the new merged entity will be known as "New Auxilium." According to the press release, this deal will expand Auxilium's platform of specialty drugs and create synergies that could lead to cost-savings.   

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.


George Budwell has no position in any stocks mentioned. The Motley Fool recommends Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers